Floatz logo

Solu-Cortef

PDAC - Pancreatic Ductal Adenocarcinoma

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the PDAC - Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Octreotide Pamoate
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4B
Serplulimab
West China Hospital
Phase 3B
Surufatinib
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2B
Irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2CCC
Ciprofloxacin
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2CCC

View all 14 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →